GlassScriptPhysician profile
Steven S Salisbury
NPI 1235191495
$7,413.47
in general payments reported to CMS, 2019-2025
44 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $1,451 · 2021: $1,624 · 2022: $1,102 · 2023: $708 · 2024: $589 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,088.68 | 2019-2024 | Farxiga |
| Amgen INC. | $1,016.71 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.96 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $625.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $535.07 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $373.10 | 2020-2024 | Xarelto |
| Amarin Pharma, INC. | $361.47 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $356.17 | 2021-2025 | |
| Abbvie INC. | $318.41 | 2019-2025 | Vraylar |
| Novo Nordisk INC | $266.17 | 2019-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.22 | 2019-2023 | Relistor |
| E.R. Squibb & Sons, L.L.C. | $158.63 | 2019-2022 | |
| Lilly USA, LLC | $156.25 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Medtronic, INC. | $115.05 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $96.71 | 2021-2023 | Freestyle Libre 2 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Salisbury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.